CUSIP: 743187106
Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
67,698,181
-
Share change
-
+542,273
-
Total reported value
-
$342,213,334
-
Put/Call ratio
-
37%
-
Price per share
-
$5.06
-
Number of holders
-
127
-
Value change
-
+$1,153,328
-
Number of buys
-
54
-
Number of sells
-
57
Quarterly Holders Quick Answers
What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2019
-
Previous quarter:
Q2 2019
Recent filing periods for CUSIP 743187106:
Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q3 2019
As of 30 Sep 2019,
PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
67,698,181 shares.
The largest 10 holders included
BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, EAGLE ASSET MANAGEMENT INC, CARILLON TOWER ADVISERS, INC., STATE STREET CORP, Point72 Asset Management, L.P., RICE HALL JAMES & ASSOCIATES, LLC, and Broadfin Capital, LLC.
This page lists
127
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.